Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
2014 · New England Journal of Medicine · 5,279 citations
https://doi.org/10.1056/nejmoa1407222
J
J. Joseph Melenhorst
Cleveland Clinic(US)
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
292
Papers
30.0K
Citations
60
h-index
128
i10-index
J. Joseph Melenhorst is an academic researcher from Cleveland Clinic. The author has contributed to research in topics: CAR-T cell therapy research & Acute Lymphoblastic Leukemia research & Immune Cell Function and Interaction. The author has an h-index of 60, co-authored 249 publications.
ORCID: 0000-0001-7677-537XPapers by this author
worksCRISPR-engineered T cells in patients with refractory cancer
2020 · Science · 1,396 citations
https://doi.org/10.1126/science.aba7365
Decade-long leukaemia remissions with persistence of CD4+ CAR T cells
2022 · Nature · 868 citations
https://doi.org/10.1038/s41586-021-04390-6
Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell
2018 · Nature Medicine · 620 citations
https://doi.org/10.1038/s41591-018-0201-9
Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial
2018 · Gastroenterology · 487 citations
https://doi.org/10.1053/j.gastro.2018.03.029
Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer
2017 · Cancer Immunology Research · 435 citations
https://doi.org/10.1158/2326-6066.cir-17-0189
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat